BAX Baxter International, Inc.
Baxter International, Inc. provides portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies; premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems; and pharmacy automation, software and services. It operates through the following segment: Americas, Europe, Middle East & Africa and Asia-Pacific. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.
Company profile
Ticker
BAX
Exchange
Website
CEO
José E. Almeida
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
Becton Dickinson & Co • 3M • Teleflex • ResMed • Hill-Rom • Boston Scientific • Integra Lifesciences • Haemonetics • NuVasive • Merit Medical Systems ...
SEC CIK
Corporate docs
IRS number
360781620
Calendar
30 Jul 19
25 Feb 20
31 Dec 20
News
Company financial data Financial data
| Quarter (USD) | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|
| Revenue | 2.84B | 2.63B | 2.84B | 2.77B | |
| Net income | 343M | 347M | 348M | 544M | |
| Diluted EPS | 0.66 | 0.66 | 0.65 | 1 | |
| Net profit margin | 12.08% | 13.18% | 12.25% | 19.66% | |
| Operating income | 355M | 384M | 398M | 385M | |
| Net change in cash | 1.02B | 76M | -1.03B | 3M | |
| Cash on hand | 2.93B | 1.91B | 1.83B | 2.86B | |
| Cost of revenue | 1.68B | 1.55B | 1.65B | 1.53B |
| Annual (USD) | Dec 18 | Dec 17 | Dec 16 | Dec 15 | |
|---|---|---|---|---|---|
| Revenue | 11.13B | 10.56B | 10.16B | 9.97B | |
| Net income | 1.62B | 717M | 4.97B | 968M | |
| Diluted EPS | 2.97 | 1.29 | 9.01 | 1.76 | |
| Net profit margin | 14.60% | 6.79% | 48.85% | 9.71% | |
| Operating income | 1.6B | 1.29B | 745M | 573M | |
| Net change in cash | -1.56B | 593M | 588M | -712M | |
| Cash on hand | 1.83B | 3.39B | 2.8B | 2.21B | |
| Cost of revenue | 6.35B | 6.09B | 6.05B | 5.78B |
Financial data from company earnings reports
Institutional ownership Q4 2019
95.8% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 1103 |
| Opened positions | 137 |
| Closed positions | 99 |
| Increased positions | 333 |
| Reduced positions | 409 |
13F shares |
Current |
|---|---|
| Total value | 106.78B |
| Total shares | 489M |
| Total puts | 1.43M |
| Total calls | 2.52M |
| Total put/call ratio | 0.6 |
Largest owners |
Shares | Value |
|---|---|---|
| Wealth Quarterback | 71.81M | $71.81B |
| BLK BlackRock | 40.8M | $3.41B |
| Vanguard | 39.3M | $3.29B |
| Wellington Management | 31.23M | $2.61B |
| STT State Street | 23.87M | $2B |
| MS Morgan Stanley | 18.03M | $1.51B |
| Third Point | 17.5M | $1.46B |
| FMR | 13.49M | $1.13B |
| AMP Ameriprise Financial | 10.42M | $871.14M |
| NTRS Northern Trust | 8.67M | $725.25M |
Financial report summary
?
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
AAKHI, absence, bundled, comparison, dedesignated, dialyzer, disease, EVO, fourth, health, Indenture, IQ, Mellon, necessitating, PrisMax, proposed, prosecution, repaid, stage, strong, Trust, Trustee, Twelfth
Removed:
adjusted, arising, core, improved, initiated, moving, nonstrategic, presenting, salary, unrecognized
Financial reports
10-Q
2019 Q2
Quarterly report
30 Jul 19
10-Q
2019 Q1
Quarterly report
8 May 19
10-K
2018 FY
Annual report
21 Feb 19
10-Q
2018 Q3
Quarterly report
5 Nov 18
10-Q
2018 Q2
Quarterly report
6 Aug 18
10-Q
2018 Q1
Quarterly report
9 May 18
10-K
2017 FY
Annual report
23 Feb 18
10-Q
2017 Q3
Quarterly report
2 Nov 17
10-Q
2017 Q2
Quarterly report
7 Aug 17
10-Q
2017 Q1
Quarterly report
4 May 17
Current reports
8-K
Results of Operations and Financial Condition
13 Feb 20
8-K
Baxter Announces Preliminary Net Sales for the Fourth-quarter and Full-year 2019 and Announces Preliminary Full-year 2020 Guidance
13 Jan 20
8-K
Entry into a Material Definitive Agreement
20 Dec 19
8-K
Baxter Receives Nyse Notice Regarding Delayed FORM10-Q Filing
22 Nov 19
8-K
Other Events
6 Nov 19
8-K
Other Events
28 Oct 19
8-K
Baxter Reports Preliminary Third Quarter 2019 Operating Results
24 Oct 19
8-K
Entry into a Material Definitive Agreement
9 Oct 19
8-K
Baxter Reports Second-quarter 2019 Results
25 Jul 19
8-K
Other Events
15 May 19
Registration and prospectus
8-A12B
Registration of securities on exchange
15 May 19
424B2
Prospectus for primary offering
14 May 19
FWP
Free writing prospectus
10 May 19
424B5
Prospectus supplement for primary offering
10 May 19
S-3ASR
Automatic shelf registration
23 Aug 18
8-A12B
Registration of securities on exchange
30 May 17
424B2
Prospectus for primary offering
22 May 17
424B5
Prospectus supplement for primary offering
19 May 17
FWP
Free writing prospectus
19 May 17
424B5
Prospectus supplement for primary offering
12 Aug 16
Proxies
DEFA14A
Additional proxy soliciting materials
26 Mar 19
DEF 14A
Definitive proxy
26 Mar 19
DEF 14A
Definitive proxy
23 Mar 18
DEFA14A
Additional proxy soliciting materials
23 Mar 18
DEF 14A
Definitive proxy
17 Mar 17
DEFA14A
Additional proxy soliciting materials
17 Mar 17
DEF 14A
Definitive proxy
24 Mar 16
DEFA14A
Additional proxy soliciting materials
24 Mar 16
PRE 14A
Preliminary proxy
14 Mar 16
DEF 14A
Definitive proxy
25 Mar 15
Other
SD
Conflict minerals disclosure
24 May 19
SD
Conflict minerals disclosure
31 May 18
SD
Conflict minerals disclosure
31 May 17
CERTNYS
Certification of approval for NYSE listing
30 May 17
UPLOAD
Letter from SEC
10 May 17
CORRESP
Correspondence with SEC
28 Apr 17
CORRESP
Correspondence with SEC
14 Apr 17
UPLOAD
Letter from SEC
31 Mar 17
NO ACT
No action letter
27 Dec 16
SD
Conflict minerals disclosure
31 May 16
Ownership
SC 13G/A
Baxter International Inc
12 Feb 20
SC 13G/A
Beneficial ownership report (amended)
5 Feb 20
SC 13G/A
Beneficial ownership report (amended)
28 Jan 20
SC 13D/A
Baxter International Inc
17 May 19
SC 13G
Baxter International Inc
12 Feb 19
SC 13G/A
Baxter International Inc
11 Feb 19
SC 13G/A
Baxter International Inc
4 Feb 19
SC 13D/A
Baxter International Inc
4 Dec 18
SC 13G/A
Baxter International Inc
12 Feb 18
SC 13G/A
Baxter International Inc
29 Jan 18
Patents
APP
Utility
Sensor Calibration
20 Feb 20
A process for calibrating a glucose sensor under sterile conditions includes providing separate, sterile, glucose-containing calibration fluids, each having a different glucose concentration, and in turn providing these fluids to a sensing zone containing a sensing probe of a glucose sensor.
APP
Utility
System for Removing Uremic Toxins In Dialysis Processes
20 Feb 20
A method of performing dialysis includes: recirculating a dialysis fluid from a patient or a dialyzer for at least two cycles, each cycle contacting the dialysis fluid first with a zirconium phosphate layer followed by at least one of a urease layer, a zirconium oxide layer, or a carbon layer; storing the recirculated dialysis fluid in a storage container; and transferring the dialysis fluid from the storage container to the patient or the dialyzer.
GRANT
Design
Inline pressure sensor and electrical connector
18 Feb 20
Inventors: Matthew Alan Bivans, William R. Griswold, Karl Hans Cazzini, Jonathan Toback, Keerthika Lakshmi Niharika Chinthapalli, Julia Radchenko, Sarah Louise Corbin, Andrea Frances Ritchie, Timothy Brian Sanchez, Ulf Quensel, Jonathan A. Handler
GRANT
Design
Inline pressure sensor and electrical connector
18 Feb 20
Inventors: Matthew Alan Bivans, William R. Griswold, Karl Hans Cazzini, Jonathan Toback, Keerthika Lakshmi Niharika Chinthapalli, Julia Radchenko, Sarah Louise Corbin, Andrea Frances Ritchie, Timothy Brian Sanchez, Ulf Quensel, Jonathan A. Handler
GRANT
Utility
Dialysis system having inventory management including online dextrose mixing
18 Feb 20
An automated peritoneal dialysis system and machine configured to perform dextrose mixing are disclosed.